These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22876945)

  • 1. Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides.
    Catena-Dell'Osso M; Fagiolini A; Marazziti D; Baroni S; Bellantuono C
    Mini Rev Med Chem; 2013 Jan; 13(1):2-10. PubMed ID: 22876945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to the pharmacological management of major depressive disorder.
    Witkin JM; Li X
    Adv Pharmacol; 2009; 57():347-79. PubMed ID: 20230766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptides: relevance in treatment of depression and anxiety disorders.
    Madaan V; Wilson DR
    Drug News Perspect; 2009; 22(6):319-24. PubMed ID: 19771321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Domino principle--monoamines in bottom-view].
    Sümegi A
    Neuropsychopharmacol Hung; 2008 Jun; 10(3):131-40. PubMed ID: 18956617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate system as target for development of novel antidepressants.
    Catena-Dell'Osso M; Fagiolini A; Rotella F; Baroni S; Marazziti D
    CNS Spectr; 2013 Aug; 18(4):188-98. PubMed ID: 23369807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
    Quesseveur G; Gardier AM; Guiard BP
    Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacological properties of antidepressants.
    Racagni G; Popoli M
    Int Clin Psychopharmacol; 2010 May; 25(3):117-31. PubMed ID: 20305568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of antidepressant action: an integrated dopaminergic perspective.
    Porcelli S; Drago A; Fabbri C; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1532-43. PubMed ID: 21402119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.
    Hoyer D; Bartfai T
    Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models of antidepressant action.
    Berman RM; Charney DS
    J Clin Psychiatry; 1999; 60 Suppl 14():16-20; discussion 31-5. PubMed ID: 10408421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
    Prins J; Olivier B; Korte SM
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
    Fornaro M; Aguglia E; Dell'Osso L; Perugi G
    Expert Opin Pharmacother; 2011 Dec; 12(18):2817-31. PubMed ID: 22098226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.
    Bymaster FP; McNamara RK; Tran PV
    Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for major depressive disorder.
    Kennedy SH; Rizvi SJ
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):439-53. PubMed ID: 19637989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New options in the treatment of depression].
    Frieling H; Hillemacher T; Demling JH; Kornhuber J; Bleich S
    Fortschr Neurol Psychiatr; 2007 Nov; 75(11):641-52. PubMed ID: 17366379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating antidepressants of the future: efficacy and safety.
    Rosenzweig-Lipson S; Beyer CE; Hughes ZA; Khawaja X; Rajarao SJ; Malberg JE; Rahman Z; Ring RH; Schechter LE
    Pharmacol Ther; 2007 Jan; 113(1):134-53. PubMed ID: 17010443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
    Chaki S; Ago Y; Palucha-Paniewiera A; Matrisciano F; Pilc A
    Neuropharmacology; 2013 Mar; 66():40-52. PubMed ID: 22640631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.